{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:28:43Z","timestamp":1794360523882,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118118","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:10:11Z","timestamp":1747181411000},"page":"118118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Esculetin inhibits liver cancer by targeting glucose-6-phosphate isomerase mediated glycolysis"],"prefix":"10.1016","volume":"188","author":[{"given":"Zongchao","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2025.118118_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of Hepatocellular Carcinoma: A Review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg."},{"issue":"5","key":"10.1016\/j.biopha.2025.118118_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: global Burden of Disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118118_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2019.188314","article-title":"Challenges in liver cancer and possible treatment approaches","volume":"1873","author":"Anwanwan","year":"2020","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118118_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156436","article-title":"Unveiling polysaccharides of Houttuynia cordata thunb.: extraction, purification, structure, bioactivities, and structure-activity relationships","volume":"138","author":"Gao","year":"2025","journal-title":"Phytomedicine"},{"issue":"10126","key":"10.1016\/j.biopha.2025.118118_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118118_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.semcancer.2021.02.015","article-title":"Cellular heterogeneity and plasticity in liver cancer","volume":"82","author":"Chan","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118118_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s43556-024-00184-0","article-title":"Signaling pathways in liver cancer: pathogenesis and targeted therapy","volume":"5","author":"Xue","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.biopha.2025.118118_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101540","article-title":"A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression","volume":"63","author":"Xu","year":"2022","journal-title":"Mol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2025.118118_bib9","first-page":"1602","article-title":"Metabolic reprogramming and its clinical implication for liver cancer","volume":"78","author":"Yang","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118118_bib10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/0008-5472.CAN-20-0948","article-title":"ASO-based PKM splice-switching therapy inhibits hepatocellular carcinoma growth","volume":"82","author":"Ma","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118118_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100976","article-title":"Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression","volume":"69","author":"Wang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"6","key":"10.1016\/j.biopha.2025.118118_bib12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s42255-024-01047-2","article-title":"Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance \u03b2-oxidation and tumor cell proliferation","volume":"6","author":"Meng","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.biopha.2025.118118_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154770","article-title":"Glycolysis, a new mechanism of oleuropein against liver tumor","volume":"114","author":"Hong","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2025.118118_bib14","article-title":"Natural products target glycolysis in liver disease","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharm."},{"issue":"24","key":"10.1016\/j.biopha.2025.118118_bib15","doi-asserted-by":"crossref","first-page":"17275","DOI":"10.3390\/ijms242417275","article-title":"Liver Cancer 2.0","volume":"24","author":"Taniguchi","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118118_bib16","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.2147\/JIR.S413941","article-title":"Esculetin alleviates inflammation, oxidative stress and apoptosis in intestinal ischemia\/reperfusion injury via targeting SIRT3\/AMPK\/mTOR signaling and regulating autophagy","volume":"16","author":"Shen","year":"2023","journal-title":"J. Inflamm. Res"},{"key":"10.1016\/j.biopha.2025.118118_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115004","article-title":"Esculetin alleviates murine lupus nephritis by inhibiting complement activation and enhancing Nrf2 signaling pathway","volume":"288","author":"Zhang","year":"2022","journal-title":"J. Ethnopharmacol."},{"issue":"20","key":"10.1016\/j.biopha.2025.118118_bib18","doi-asserted-by":"crossref","first-page":"12643","DOI":"10.3390\/ijms232012643","article-title":"Pharmacological and therapeutic applications of esculetin","volume":"23","author":"Garg","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118118_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/JHC.S395617","article-title":"Inhibitory effects of esculetin on liver cancer through triggering NCOA4 pathway-mediation ferritinophagy in vivo and in vitro","volume":"10","author":"Xiu","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"4","key":"10.1016\/j.biopha.2025.118118_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23702","article-title":"Protective effects of esculetin against doxorubicin-induced toxicity correlated with oxidative stress in rat liver: in vivo and in silico studies","volume":"38","author":"K\u00f6ro\u011flu","year":"2024","journal-title":"J. Biochem Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118118_bib21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1186\/s12885-024-12736-2","article-title":"Targeting cellular plasticity: esculetin-driven reversion of stem cell-like characteristics and EMT phenotype in transforming cells with sequential p53\/p73 knockdowns","volume":"24","author":"Mathur","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2025.118118_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.freeradbiomed.2019.11.022","article-title":"Bioactive ingredients obtained from cortex fraxini impair interactions between FAS and GPI","volume":"152","author":"Wu","year":"2020","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.biopha.2025.118118_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.foodchem.2016.11.124","article-title":"Binding properties of the natural red dye carthamin with human serum albumin: surface plasmon resonance, isothermal titration microcalorimetry, and molecular docking analysis","volume":"221","author":"He","year":"2017","journal-title":"Food Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118118_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13046-022-02415-0","article-title":"Aberrant miR-874-3p\/leptin\/EGFR\/c-Myc signaling contributes to nasopharyngeal carcinoma pathogenesis","volume":"41","author":"Luo","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"17","key":"10.1016\/j.biopha.2025.118118_bib25","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.3390\/ijms231710037","article-title":"Revisited metabolic control and reprogramming cancers by means of the warburg effect in tumor cells","volume":"23","author":"Fukushi","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118118_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.700629","article-title":"Mechanisms governing metabolic heterogeneity in breast cancer and other tumors","volume":"11","author":"Patra","year":"2021","journal-title":"Front Oncol."},{"issue":"Pt 2","key":"10.1016\/j.biopha.2025.118118_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semcancer.2022.07.004","article-title":"Warburg effect' controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives","volume":"86","author":"Pouyss\u00e9gur","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.biopha.2025.118118_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106995","article-title":"RHBDF1 deficiency suppresses melanoma glycolysis and enhances efficacy of immunotherapy by facilitating glucose-6-phosphate isomerase degradation via TRIM32","volume":"198","author":"Wang","year":"2023","journal-title":"Pharm. Res"},{"issue":"Pt 3","key":"10.1016\/j.biopha.2025.118118_bib29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.semcancer.2022.09.007","article-title":"Tumor glycolysis, an essential sweet tooth of tumor cells","volume":"86","author":"Paul","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118118_bib30","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/ijms24032606","article-title":"Modulating glycolysis to improve cancer therapy","volume":"24","author":"Chelakkot","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118118_bib31","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.3390\/ijms22094716","article-title":"Hexokinase 2 in cancer: a prima donna playing multiple characters","volume":"22","author":"Ciscato","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118118_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189089","article-title":"Exploring the diverse role of pyruvate kinase M2 in cancer: navigating beyond glycolysis and the Warburg effect","volume":"1879","author":"Upadhyay","year":"2024","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2025.118118_bib33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.biopha.2025.118118_bib34","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1038\/onc.2014.320","article-title":"How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?","volume":"34","author":"Lincet","year":"2015","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2025.118118_bib35","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202302559R","article-title":"Poly(ADP-ribose) mediates bioenergetic defects and redox imbalance in neurons following oxygen and glucose deprivation","volume":"38","author":"Hossain","year":"2024","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.biopha.2025.118118_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12272-023-01431-8","article-title":"Tumor lactic acid: a potential target for cancer therapy","volume":"46","author":"Byun","year":"2023","journal-title":"Arch. Pharm. Res"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:58:50Z","timestamp":1778543930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":36,"alternative-id":["S0753332225003129"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118118","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Esculetin inhibits liver cancer by targeting glucose-6-phosphate isomerase mediated glycolysis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118118"}}